Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.Based on a recent peer-reviewed paper published in January 2014 in the British Journal of Clinical Pharmacology Richmond Pharmacology will present its latest findings as an encore poster presentation at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), taking place 18th to 22nd March, in Atlanta, Georgia.Join Richmond Pharmacology s Dr Jorg Taubel on 21st March between 11h45 and 13h15 (poster number EII-001) for insight into this new area of research.Read Full PaperView Meeting Program

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event